Serious Doubts on Safety and Efficacy of CCR5 Antagonists

Horster, S.; Goebel, F.
April 2006
Infection;Apr2006, Vol. 34 Issue 2, p110
Academic Journal
The article reports on the separate clinical trials involving CCR5 antagonists, GlaxoSmithKline's aplaviroc, Pfizer's maraviroc and Schering-Plough's vicriviroc, in patients with AIDS. In healthy volunteers, the substances exhibited an efficacy to prevent the propagation of virus strains with all kinds of mutations. CCR5 seemed a promising target for co-receptor antagonists as a natural deletion in the CCR5 encoding region enables individuals to resist HIV infection or delay HIV disease progression. The clinical trials have failed to clarify the mechanisms of resistance development during treatment with CCR5 receptor antagonist.


Related Articles

  • Fresh Mechanisms to Fight Resistant Viruses. Hirsch, Martin S. // Pharmaceutical Executive;Dec2005, Vol. 25 Issue 12, p64 

    The article presents information about new mechanisms to fight resistant AIDS viruses. They include L 870810 integrase inhibitor from Merck, JTK 303 integrase inhibitor by Japan Tobacco Inc., Maraviroc entry inhibitor by Pfizer Inc., GW 873140 entry inhibitor by GlaxoSmithKline PLC, Vicriviroc...

  • DTC REPORT: Update.  // Medical Marketing & Media;Nov2008, Vol. 43 Issue 11, p28 

    The article offers news briefs related to pharma companies. The AIDS Healthcare Foundation has applauded the suspension of several print advertisements for Lexiva HIV treatment from GlaxoSmithKline. The company and Schering-Plough Corp. have awarded the consumer advertising business for Levitra...

  • Two CCR5 entry inhibitor studies cancelled, one remaining. Appleby, Jason // HIV Australia;Jul-Sep2005, Vol. 5 Issue 1, p28 

    Presents updates on the clinical trials conducted by major drugs companies who were in a race to be the first in the market with a new kind of antiretroviral that blocks the HIV virus before it even enters the cells. Announcement by Glaxo SmithKline that is calling a halt in phase II studies...

  • Update.  // Medical Marketing & Media;Apr2009, Vol. 44 Issue 4, p9 

    The article offers news briefs related to medical marketing in the U.S. The new album of Wynonna Judd will be given to consumers who purchase the weight loss drug Alli of GlaxoSmithKline. Kathryn Metcalfe is named as corporate reputation and policy communication of Pfizer Inc. The Clear to Drive...

  • In Other News.  // Pharmaceutical Representative;Sep2005, Vol. 35 Issue 9, p14 

    Presents news briefs pertaining to the pharmaceutical industry in the United States as of September 2005. Purdue Pharma LP's voluntary suspension of the sales and marketing of its narcotic painkiller Palladone (hydromorphone hydrochloride); Food and Drug Administration's approval of the labeling...

  • Market Summary.  // U.S. Pharma & Healthcare Report;Q1 2009, p11 

    The article discusses the performance of the U.S. pharmaceutical market as of the first quarter of 2009. The U.S. has the highest per capita drug spending in the world, and many of the major pharmaceutical companies are based in the country, including Pfizer, Eli Lilly and Schering-Plough. The...

  • High Anxiety: Patents Expire, Successes Wane. Bittar, Christine // Brandweek;6/17/2002, Vol. 43 Issue 24, pS64 

    Highlights the economics and advertising aspects of the pharmaceutical industry in the U.S.. Problems facing Schering-Plough with its Clarinex drug; Competition facing the Viagra drug of Pfizer Inc.; Total increase in advertising spending of pharmaceutical firms in 2001; Outlook on advertising...

  • Pharmaceutical Company Round-up.  // PharmaWatch: Monthly Review;Apr2009, Vol. 8 Issue 4, p3 

    The article offers global news briefs related to the pharmaceutical industry. Merck & Co. Inc. and Schering-Plough Corp. are planning to merge and create a new company. Pfizer Inc. announces the Phase III trial of the drug Sutent for advanced pancreatic neuroendocrine tumors. The European...

  • Vertex Stock Slides On Schering's Positive Data.  // Bioworld Week;10/22/2007, Vol. 15 Issue 43, p5 

    The article reports that the shares of Vertex Pharmaceuticals Inc. of Cambridge, Massachusetts has dropped by 13.2% due to Phase II clinical trial data from Kenilworth, New Jersey-based Schering-Plough Corp.'s oral hepatitis C protease inhibitor. Schering's boceprevir combined with Pegintron and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics